Novel antibiotic candidate (PZ-601) focused on drug resistance in difficult to treat infections. Acquired by Novartis in 2008.
© 2024 BioAdvance. All Rights Reserved. | Privacy Policy | Site by Loudmark
101 West Elm Street, Suite 330, Conshohocken, PA 19428 | (610) 230-0544